CAMP4 Therapeutics Corporation

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: CAMP4 Therapeutics Corporation
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Watertown
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: CAMP
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001736730

Board of directors

Follow this board

Amir Nashat · Director
Since 2024
Andrew J. Schwab · Director
Since 2024
Douglas E. Williams · Director
Since 2025
Ingo Chakravarty · Director
Since 2024
James P. Boylan · Director
Since 2024
Josh Mandel-Brehm · Director · Chief Executive Officer
Since 2024
Michael F. MacLean · Director
Since 2026
Michael J. Higgins · Director
Since 2024
Murray Stewart · Director
Since 2025
Paula Ragan · Director
Since 2024
Ravi I. Thadhani · Director
Since 2024
Richard A. Young · Director
Since 2024
Steven H. Holtzman · Director
Since 2024

Chief executives

Josh Mandel-Brehm · Chief Executive Officer

Since October 2024

100 CEO score

Outstanding · grade A+

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 20% of the scoring weight is on file.

Revenue growth 20%: 100

20% of the scoring weight is on file. Figures cover December 2023 – December 2025.

Director election results

Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Richard A. Young

78.5%
Steven H. Holtzman

78.5%

Board connections

9 of this board's directors also sit on 14 other boards. 14 are in the same sector.

Shared director Other board Same sector

X4 Pharmaceuticals Inc. Same sector
via Murray Stewart and Paula Ragan
Amarin Corporation plc Same sector
via Murray Stewart
Climb Bio Inc. Same sector
via Douglas E. Williams
Compass Therapeutics Inc. Same sector
via James P. Boylan
Enliven Therapeutics Inc. Same sector
via Andrew J. Schwab
Immunome Inc. Same sector
via James P. Boylan
Korsana Biosciences Inc. Same sector
via Michael J. Higgins
ProMIS Neurosciences Inc. Same sector
via Josh Mandel-Brehm
Pulmatrix Inc. Same sector
via Michael J. Higgins
Research Alliance Corporation III Same sector
via Michael F. MacLean
Scholar Rock Holding Corporation Same sector
via Amir Nashat
Skye Bioscience Inc. Same sector
via Andrew J. Schwab
Voyager Therapeutics Inc. Same sector
via Michael J. Higgins
Zenas BioPharma Inc. Same sector
via James P. Boylan

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $99,051; 5 purchases by 4 insiders
Sold, last 12 months: $2,504,037; 6 sales by 2 insiders

Date	Insider	Transaction	Shares	Price	Value
Aug 31, 2026	Kelly Gold Officer (Chief Financial Officer)	Open-market purchase	+10,000	$3.96	$39,600
Aug 27, 2026	Andrew J. Schwab Director	Open-market sale	−400,000	$4.04	$1,616,000
Aug 24, 2026	Andrew J. Schwab Director	Open-market sale	−10	$4.50	$45
Aug 21, 2026	Andrew J. Schwab Director	Open-market sale	−32,018	$4.50	$144,081
Aug 20, 2026	Andrew J. Schwab Director	Open-market sale	−114,700	$4.54	$520,738
Aug 19, 2026	Tardiff Daniel Officer (Chief Scientific Officer)	Open-market sale	−1,738	$4.76	$8,273
Aug 19, 2026	Andrew J. Schwab Director	Open-market sale	−45,147	$4.76	$214,900
Aug 3, 2026	Josh Mandel-Brehm Director, Officer (Chief Executive Officer)	Open-market purchase	+6,551	$1.65	$10,809
Aug 3, 2026	Kelly Gold Officer (Chief Financial Officer)	Open-market purchase	+6,551	$1.65	$10,809
Aug 3, 2026	Maricich Yuri Officer (Chief Medical Officer)	Open-market purchase	+6,551	$1.65	$10,809
Aug 3, 2026	Richard A. Young Director	Open-market purchase	+16,378	$1.65	$27,024
Sep 11, 2025	Andrew J. Schwab Director, 10% owner	Grant or award	+2,941,176	$1.53	$4,499,999
Sep 11, 2025	5AM Ventures VII, L.P. 10% owner	Open-market purchase	+2,941,176	$1.53	$4,499,999
Sep 11, 2025	Polaris Management Co. VII, L.L.C. 10% owner	Open-market purchase	+1,221,721	$1.53	$1,869,233
Sep 11, 2025	Amir Nashat Director, 10% owner	Open-market purchase	+1,221,721	$1.53	$1,869,233

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about CAMP4 Therapeutics Corporation

Who is the CEO of CAMP4 Therapeutics Corporation?

Josh Mandel-Brehm has been CAMP4 Therapeutics Corporation's Chief Executive Officer since October 2024.

How many directors are on CAMP4 Therapeutics Corporation's board?

CAMP4 Therapeutics Corporation's board has 13 directors: Amir Nashat, Andrew J. Schwab, Douglas E. Williams, Ingo Chakravarty, James P. Boylan, Josh Mandel-Brehm, Michael F. MacLean, Michael J. Higgins, Murray Stewart, Paula Ragan and 3 others.

Are CAMP4 Therapeutics Corporation insiders buying or selling shares?

Over the last 12 months, CAMP4 Therapeutics Corporation insiders bought $99,051 of shares in 5 purchases and sold $2.5 million of shares in 6 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is CAMP4 Therapeutics Corporation connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="camp4-therapeutics-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.